Skip to main content

Table 4 Treatment emergent adverse effects in the study participants

From: Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Characteristic Placebo
(n = 65)
Rasagiline 1 mg
(n = 65)
Patients with TEAEs 30 (46.2) 27 (41.5)
 SAEs 4 (6.2) 0 (0)
 TEAEs leading to withdrawal 5 (7.7) 3 (4.6)
Nervous system disorder 10 (15.4) 13 (20.0)
 Bradykinesia 0 (0) 1 (1.5)
 Dizziness 3 (4.6) 3 (4.6)
 Headache 0 (0) 2 (3.1)
 Parkinson’s diseasea 4 (6.2) 5 (7.7)
 Poor quality sleep 0 (0) 1 (1.5)
 Somnolence 0 (0) 2 (3.1)
 Speech disorder 1 (1.5) 0 (0)
 Tremor 3 (4.6) 3 (4.6)
Gastrointestinal disorders 7 (10.8) 5 (7.7)
 Abdominal discomfort 2 (3.1) 0 (0)
 Constipation 0 (0) 1 (1.5)
 Diarrhea 1 (1.5) 2 (3.1)
 Dry mouth 1 (1.5) 1 (1.5)
 Gastric dilation 1 (1.5) 0 (0)
 Nausea 1 (1.5) 0 (0)
Psychiatric disorders 2 (3.1) 2 (3.1)
 Hallucination 0 (0) 1 (1.5)
 Insomnia 1 (1.5) 1 (1.5)
 Major depression 1 (1.5) 0 (0)
Eye disorders 1 (1.5) 2 (3.1)
  1. Data are n (%). TEAE, treatment-emergent adverse event. SAE, serious adverse event
  2. aParkinson’s disease means the worsening or progression of Parkinson’s disease